The obesity paradox in metastatic castration-resistant prostate cancer

Alberto Martini(The University of Texas MD Anderson Cancer Center), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), Francesco Montorsi(Vita-Salute San Raffaele University), Emily J. Gallagher(Icahn School of Medicine at Mount Sinai), Andrea Necchi(Vita-Salute San Raffaele University), Qainat N. Shah(Icahn School of Medicine at Mount Sinai), Nikhil Waingankar(Icahn School of Medicine at Mount Sinai), Che‐Kai Tsao(Mount Sinai Hospital), John P. Sfakianos(Mount Sinai Medical Center)
Prostate Cancer and Prostatic Diseases
July 5, 2021
10.1038/s41391-021-00418-0
Cited by 33

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k